Dow Jones 30 Stocks SEC Filings — March 30, 2026

30-03-2026

Hennessy Capital Investment Corp. VIII (HCIC), a blank-check SPAC incorporated in the Cayman Islands, filed its 10-K annual report on March 30, 2026, with no operational revenue and emphasis on risks associated with identifying and completing an initial business combination within a 24-month window from its IPO closing. The filing details the sponsor's private placement of 671,000 units for $6,710,000 and permitted withdrawals limited to 5.0% annually of trust account interest, while highlighting a seasoned board of directors with extensive M&A and industry experience but noting potential conflicts and liquidity challenges. Standard SPAC risks dominate, including no target identified, trust account vulnerabilities, and market volatility impacting deal completion.

• ·Completion window of 24 months from IPO closing to consummate initial business combination, after which public shares are redeemable at approximately $10.00 per share
• ·Trust account interest subject to permitted withdrawals for working capital (up to 5.0% annually) and taxes (excluding excise taxes), but principal protected
• ·No operational revenue or established track record as a pre-combination SPAC

30-03-2026

Ingevity Corporation, along with Ingevity Holdings SRL and Ingevity UK Ltd, entered into a Second Amendment and Restatement Agreement dated March 26, 2026, amending their existing credit agreement to establish new Revolving Commitments totaling $750 million, with proceeds used to repay all outstanding revolving loans under the prior facility. The transaction involves JPMorgan Chase Bank, N.A. as Administrative Agent and other lenders, with effectiveness subject to standard conditions including legal opinions, solvency certificates, and repayment of prior obligations. No comparative financial metrics or performance declines are disclosed in the filing.

• ·Existing Credit Agreement originally dated June 23, 2022
• ·Amendment Arrangers: JPMorgan Chase Bank, N.A., BofA Securities, Inc., Citizens Bank, N.A., PNC Bank, National Association, TD Securities (USA) LLC
• ·Legal opinions required from Wachtell, Lipton, Rosen & Katz, McGuireWoods LLP, Loyens & Loeff CVBA, NautaDutilh BV/SRL, Cahill Gordon & Reindel (UK) LLP
• ·Engagement Letter dated February 19, 2026

30-03-2026

CBAK Energy reported explosive Q4 2025 consolidated net revenues of $58.80 million, up 131.8% YoY from $25.37 million, fueled by 524.2% growth in Light Electric Vehicles (LEV) to $12.92 million and 944.1% surge in Hitrans battery raw materials to $27.98 million; however, Electric Vehicles declined 91.1% to $0.06 million and Residential Energy Supply & UPS fell 10.6% to $17.84 million. Full year 2025 revenues grew 11% to $195.19 million from $176.61 million, with LEV up 252% to $36.36 million and Hitrans up 123% to $89.21 million, but Battery Business total dropped 22% due to a 45% decline in Residential Energy Supply & UPS to $68.82 million, resulting in gross margin compression to 9.4% from 23.7% and a net loss of $9.38 million versus $11.79 million net income in 2024.

• ·Q4 2025 gross profit $4.28M (margin 7.3%) vs $3.31M (13.1%) in Q4 2024.
• ·FY 2025 cost of revenues $176.77M including $6.61M inventory write-downs.
• ·Q4 2025 operating loss $8.01M vs $6.59M in Q4 2024; FY 2025 operating loss $18.44M vs $8.79M income in FY 2024.
• ·Q4 R&D expenses $5.30M (up from $3.80M); FY R&D $15.80M (up 21%).
• ·Cash increased to $75.68M as of Dec 31, 2025 from $60.79M.

30-03-2026

Unicycive Therapeutics reported full year 2025 financial results with a reduced net loss attributable to common stockholders of $26.6 million ($1.67 per share) compared to $37.8 million ($5.65 per share) in 2024, driven by lower R&D expenses of $9.1 million versus $20.0 million, though G&A expenses rose to $20.4 million from $12.1 million amid commercial launch preparations. As of March 30, 2026, unaudited cash, cash equivalents, and marketable securities totaled $54.9 million, supporting operations into 2027. The FDA accepted the OLC NDA resubmission in January 2026, setting a PDUFA target action date of June 29, 2026.

• ·FDA accepted OLC NDA resubmission in January 2026, supported by three clinical studies, preclinical data, and CMC; no concerns on preclinical, clinical, or safety data from original NDA.
• ·OLC resubmission in December 2025 addressed drug product manufacturing by third-party vendor.
• ·UNI-494 granted orphan drug designation for prevention of Delayed Graft Function in kidney transplant patients; completed Phase 1 dose-ranging safety study.
• ·Stockholders’ equity increased to $30.2 million as of Dec 31, 2025 from $7.4 million as of Dec 31, 2024.

30-03-2026

Volato Group, Inc. entered into an ATM Sales Agreement with Curvature Securities, LLC to offer and sell up to $3,700,000 of Class A Common Stock at-the-market. The company provided an update on its pending merger with M2i Global, Inc., where M2i shareholders are expected to receive approximately 85% ownership of the combined company (via ~119.2M shares), resulting in significant dilution for existing Volato shareholders who will hold ~15%. The merger faces risks including stockholder approvals, integration challenges, operational disruptions, and potential failure to realize strategic benefits.

• ·ATM sales made via methods permitted under Rule 415, including directly on NYSE American LLC.
• ·Merger Agreement originally dated July 28, 2025; shelf registration on Form S-3 (File No. 333-290219) effective September 30, 2025.
• ·Company plans to seek stockholder approval for potential reverse stock split to meet NYSE American listing requirements.
• ·Merger closing subject to M2i Global and Volato stockholder approvals, with risks of delays, termination, or adverse business impacts.

30-03-2026

AIxCrypto Holdings reported total assets of $31,279,846 as of December 31, 2025, up significantly from $4,686,519 in 2024, driven by cash and cash equivalents rising to $19,332,707 and new digital assets of $10,250,497, bolstered by $40,991,044 in financing activities including $4.5 million from Series A-3 Preferred and substantial Series B Preferred issuances. However, the company posted a larger net loss attributable to shareholders of $19,528,742 in 2025 versus $6,346,795 in 2024, with total expenses increasing 129% to $13,202,096 due to higher general and administrative costs and a $4,195,000 credit loss expense, alongside a $3,588,106 net loss on digital assets. Stockholders’ equity grew to $27,950,609 from $2,679,036, but operating cash use worsened slightly to $(6,951,458).

• ·Short-term notes receivable net: $343,060 (2025) vs $2,010,692 (2024), after allowance of $4.6M (2025) vs $360,000 (2024).
• ·Related party payable: $1,648,945 (2025) vs $0 (2024).
• ·Issuance of $4,166,900 notes receivable to a publicly traded entity from Apr 2024-Dec 2025 at 18% interest.
• ·Secured Convertible Note $264,000 principal (+$44,000 OID) issued Apr 2025, repaid Jan 2026.
• ·Subscription agreement Sept 19, 2025 for $41M: issued 337,432 common shares and 17,783 Series B shares by Sept 29, 2025.

30-03-2026

Vine Hill Capital Investment Corp. shareholders overwhelmingly approved the business combination with CoinShares International Limited at the March 27, 2026 extraordinary general meeting, with 92.6% of votes cast in favor of the Business Combination Proposal (22,095,264 For vs. 1,764,990 Against). The company notified Nasdaq on March 24, 2026, of its intent to voluntarily delist its units (VCICU), Class A ordinary shares (VCIC), and warrants (VCICW) following the merger closing, with Odysseus Holdings Limited's ordinary shares and warrants expected to list on Nasdaq thereafter. The transaction is anticipated to close on March 31, 2026, subject to customary conditions including Jersey regulatory approvals.

• ·Shareholder Meeting quorum: holders of 16,526,920 Class A and 7,333,334 Class B ordinary shares present, representing 81.342% of voting power as of record date March 2, 2026.
• ·All Shareholder Proposals approved, including SPAC Merger Proposal (identical vote to Business Combination), Organizational Document Proposals (some with 150,000 abstentions), and NTA Proposal (23,685,207 For, 25,047 Against, 150,000 Abstain).
• ·Registration Statement on Form F-4 (No. 333-293885) declared effective March 16, 2026; Proxy Statement mailed same day.
• ·Merger structure: SPAC merges into SPAC Merger Sub (Odysseus (Cayman) Limited) on March 30, 2026, followed by scheme of arrangement acquiring CoinShares on March 31, 2026.

30-03-2026

Boeing Co (BA-PA) filed a DEFA14A Definitive Additional Proxy Statement on March 30, 2026. The provided content consists solely of standard boilerplate language referencing SEC filings such as Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, along with a forward-looking statements disclaimer. No specific financial data, proposals, or material updates are detailed in the excerpt.

30-03-2026

Empire District Bondco, LLC's 10-K annual report details its directors, executive officers, and corporate governance under Item 10. The leadership includes Tim Wilson (48, Manager and President, appointed January 17, 2025), Fraser McNamee (41, Manager, Treasurer, and Secretary, appointed September 15, 2025), and Jennifer A. Schwartz (52, Independent Manager with extensive capital markets experience). No financial performance metrics or changes are highlighted in this section.

• ·Tim Wilson's prior roles: President of Central Region – Electric for Liberty Utilities Service Corp. (since July 2023), VP Electric Operations (2020-2023), VP Strategic Projects and Energy Supply (2019-2020), Central Region Director of Electric Operations – Services (2017-2019).
• ·Fraser McNamee's prior roles: VP Finance and Corporate Controller for Algonquin (since April 2023), Senior Director Accounting and Reporting (2022-2023), Director of Finance (2017-2022).
• ·Jennifer A. Schwartz: 25 years in U.S. and global capital markets, serves as independent director/manager for bankruptcy remote transactions, Delaware statutory trusts since 2004.

30-03-2026

Global Arena Holding, Inc. reported services revenues of $399,263 for Q1 2025, up 72% YoY from $232,123. However, operating expenses more than doubled to $476,752 from $179,245, resulting in an operating loss of $77,489 versus a $52,878 profit last year, and net loss widened to $288,123 from $131,018. Operating cash flow turned negative at $(60,840) from $7,067 provided, though financing activities contributed $194,431 mainly from convertible notes.

• ·Dilutive securities outstanding: 1,164,583,333 warrants and 1,219,682,923 convertible notes as of March 31, 2025 (down from 2,997,606,346 prior year).
• ·Fair value of beneficial conversion feature: $9,922 at March 31, 2025 (Level 2 input), down from $20,799 at December 31, 2024.
• ·Loss per share remained $(0.00) basic and diluted for both periods.

30-03-2026

Endeavour Silver Corp (EXK) filed its 40-F Annual Report for the year ended December 31, 2025, including audited consolidated financial statements by KPMG LLP for 2025 and 2024, MD&A, and Annual Information Form. Audit fees increased 64.8% YoY to $1,910,726 from $1,159,465, while tax fees and all other fees remained flat at $0 for both years.

• ·Financial statements cover years ended December 31, 2025 and 2024.
• ·Auditor: KPMG LLP (Vancouver, BC, Canada; Auditor Firm ID: 85).
• ·Filing includes Inline XBRL documents (Exhibits 101.INS through 101.PRE).

30-03-2026

Reviva Pharmaceuticals reported a reduced net loss of $19.9 million for FY2025 ($5.48 per share) compared to $29.9 million ($17.73 per share) in FY2024, driven by lower R&D expenses ($11.7M vs. $22.9M), with cash at $14.4M at year-end and ~$23M post-March 2026 offering to fund into Q1-2027. However, G&A expenses rose slightly to $8.5M, and FDA feedback requires a second Phase 3 RECOVER-2 trial in mid-2026 before NDA for brilaroxazine in schizophrenia, despite positive 1-year OLE data showing sustained efficacy (PANSS total -18.1) and favorable safety. The company raised $29M gross via three equity offerings in 2025-2026.

• ·1-year OLE: PANSS total score improvement -18.1; positive symptoms -5.0; negative symptoms -4.4; <1% relapse.
• ·Weight gain ~1.5 kg over 52 weeks; no clinically meaningful movement disorders; favorable lipids, glucose, prolactin normalization.
• ·NDA-enabling carcinogenicity studies completed; cGMP manufacturing of drug substance and product batches done.
• ·Three new U.S. provisional patents filed; EP3749324 granted for pulmonary fibrosis.

30-03-2026

Accelerant Holdings, an emerging growth company under the JOBS Act, has issued its proxy statement for the hybrid 2026 Annual General Meeting on May 12, 2026, at 10:00 a.m. BST in London or via webcast, with pre-registration required at https://web.viewproxy.com/arx/2026. Shareholders of record as of March 13, 2026, will vote on electing three Class I directors for three-year terms expiring in 2029 and ratifying PricewaterhouseCoopers LLP as independent auditor for the year ending December 31, 2026. As of the record date, 222,160,004 common shares are outstanding, comprising 116,757,858 Class A shares (1 vote each) and 105,402,146 Class B shares (10 votes each), with a simple majority quorum required.

• ·Quorum requires holders of a simple majority of common shares present in person or by proxy.
• ·Proxy deadlines: mail by May 11, 2026; internet at www.AALvote.com/ARX by 11:59 p.m. ET on May 11, 2026.
• ·Election of directors requires simple majority of votes cast; ratification of PwC requires majority of votes cast at meeting with quorum.
• ·No cumulative voting in director elections; abstentions and broker non-votes do not impact proposals.

30-03-2026

General Enterprise Ventures, Inc. reported revenue of $2,381,407 for the year ended December 31, 2025, marking a 195% increase from $808,372 in 2024. However, operating expenses surged 209% to $18,877,398, other expenses skyrocketed 1,190% to $20,341,652, and the net loss widened dramatically by 435% to $36,837,643 from $6,881,722. The company highlighted ongoing risks including high leverage, stock volatility, dilution from share issuances, and challenges in achieving profitability.

• ·Recent sales of unregistered securities included 220,000 shares for IP acquisition valued at $1,775,400 from Breakthrough Chemistry, Inc.
• ·346,127 shares issued via cashless conversion of 359,375 warrants.
• ·500,000 shares issued upon conversion of 150,000 shares of Series C Convertible Preferred Stock.
• ·475,862 shares issued for conversion of $1,071,821 in debt and accrued interest.
• ·55,333 shares issued for services valued at $443,377.

30-03-2026

Soluna Holdings, Inc. filed an S-3/A amendment to its shelf registration statement (No. 333-294152) on March 30, 2026, registering securities including preferred stock, warrants, debt indentures, notes, and units. The filing primarily lists exhibits incorporated by reference from prior SEC reports, such as various certificates of amendment and designations for Series A and Series B preferred stock. It is signed by CEO John Belizaire and other executives and directors in Albany, New York, with no financial performance data or period comparisons disclosed.

• ·Registration No. 333-294152
• ·References prior filings including 2020 Form 10-K and multiple 8-Ks up to November 10, 2025
• ·Exhibits marked * filed herewith, ** previously filed, *** or † to be filed by amendment

30-03-2026

RYVYL Inc. reported that RTB Digital, Inc., its proposed merger partner (with Ryvyl as surviving entity), entered a confidential Strategic Partnerships and Investment Terms Agreement to acquire a controlling interest in a strategically aligned company, including a $10 million non-refundable deposit applied to the final purchase price. Upon merger consummation, Ryvyl will assume the agreement through its wholly owned subsidiary RTB. Negotiations on certain terms continue, expected to resolve within 30 days, subject to conditions like funding, additional purchase price payment, and assumption of seller debt.

• ·Date of earliest event: March 25, 2026
• ·Filing date: March 30, 2026
• ·Substantive conditions for Strategic Agreement consummation include funding, payment of additional purchase price, and RTB assuming a portion of seller group outstanding debt

30-03-2026

Osisko Development Corp. filed its Form 40-F Annual Report on March 30, 2026. The filing lists the company's Common Shares (no par value, trading symbol ODV) registered on the New York Stock Exchange and Warrants (exercisable for one Common Share at $10.70, trading symbol ODVWZ) on The Nasdaq Stock Market LLC.

30-03-2026

Artificial Intelligence Technology Solutions, Inc. (AITX) filed an 8-K on March 30, 2026, under Item 8.01 to furnish a press release titled 'AITX's RAD Reports Its Strongest ISC West Showing to Date,' attached as Exhibit 99.1. The filing notes that the information is furnished and not deemed filed for liability purposes. No financial metrics or period comparisons are disclosed.

• ·Filing Type: 8-K (Items 8.01, 9.01)
• ·Date of Report: March 30, 2026
• ·Registrant State: Nevada; CIK: 0001498148; EIN: 27-2343603
• ·Principal Address: 10800 Galaxie Avenue, Ferndale, Michigan 48220

30-03-2026

A Paradise Acquisition Corp. is pursuing a business combination with Enhanced Ltd., the company behind the Enhanced Games, which has launched an online personalized performance medicine platform offering proprietary supplements, hormone therapy, and peptides like Sermorelin, with plans to expand to seven more if FDA regulations ease on 14 Category 2 peptides. The global peptide therapeutics market is estimated at $52B today, potentially reaching $87B by 2035, with $15B in the US portion of an $80B market, presenting significant opportunities. However, Enhanced has an unproven business model, limited operating history, and minimal revenue to date, alongside regulatory, ethical, and competitive risks.

• ·Inaugural Enhanced Games event scheduled for May 24, 2026 in Las Vegas
• ·Platform launched less than a month ago with positive early DTC metrics (volume, visits, average order size, cart adds) on small numbers
• ·Form S-4 registration statement filed with SEC, including proxy statement/prospectus

30-03-2026

Aldabra 4 Liquidity Opportunity Vehicle, Inc. (ALOV), a blank check company incepted on July 24, 2025, reported total assets of $285,064, including $23,583 in cash and $261,481 in deferred offering costs, as of December 31, 2025. Total liabilities stood at $338,146, resulting in a shareholder’s deficit of $53,082, with a net loss of $78,082 for the period from inception through December 31, 2025, driven entirely by formation and general administrative expenses and no revenue.

• ·Accounts payable: $11,246 as of December 31, 2025
• ·Accrued expenses: $13,125 as of December 31, 2025
• ·Accrued offering costs: $113,775 as of December 31, 2025
• ·Basic and diluted net loss per Class B ordinary share: ($0.01)
• ·Class B ordinary shares authorized: 20,000,000

30-03-2026

HCM IV Acquisition Corp., a blank check company and shell entity, reported total assets of $160,959, primarily consisting of $25,000 in prepaid expenses and $135,959 in deferred offering costs as of December 31, 2025. The company recorded a net loss of $59,655 from formation and administrative costs for the period from inception (September 5, 2025) through December 31, 2025, resulting in total liabilities of $195,614 (including a $154,819 related party promissory note) and a shareholders' deficit of $34,655, with zero cash on hand at period end.

• ·Entity is a shell company (true), emerging growth company (true), small business (true), and non-accelerated filer.
• ·Entity Central Index Key: 0002089982; Entity Tax ID: 98-1883478.
• ·Address: 85 Washington St, 1F, Stamford, CT 06854; Phone: (203) 930-2200.
• ·Securities listed on NASDAQ.
• ·Basic and diluted net loss per Class B share: $(0.01).
• ·Net cash used in operating activities: $0.

30-03-2026

707 Cayman Holdings Ltd., a Cayman Islands exempted company listed on Nasdaq Capital Market since June 9, 2025, filed an F-1 registration statement on March 27, 2026, to register securities with the SEC. The filing discloses significant risks including limited shareholder rights and enforcement challenges under Cayman Islands law, reduced reporting as an emerging growth company and foreign private issuer, increased compliance costs from public listing, and regulatory scrutiny on emerging market companies (e.g., China/Hong Kong) related to PCAOB audit inspections under HFCA Act and AHFCAA, potentially leading to delisting.

• ·Nasdaq listing date: June 9, 2025
• ·Annual report on Form 20-F due within four months of fiscal year-end
• ·Semi-annual financial results via press releases furnished on Form 6-K
• ·SEC/PCAOB joint statements: December 7, 2018; April 21, 2020
• ·HFCA Act: U.S. Senate May 20, 2020; House December 2, 2020
• ·Nasdaq proposals filed: May 21, 2021
• ·Senate AHFCAA passage: June 22, 2021

30-03-2026

Gores Holdings X, Inc., a SPAC, completed its IPO in 2025, raising $358,800,000 in proceeds and funding the Trust Account to $367,742,183, with net income of $920,659 driven by $9,511,647 in interest income. However, the company reported an operational net loss of $1,850,155, a $6,637,800 expense from change in fair value of public warrant liabilities, and basic/diluted net loss per share of $(0.76) across all classes due to accretion of temporary equity, resulting in shareholders' deficit widening to $(31,301,532) from $(40,000). Total assets grew significantly to $368,717,492 from $1,184,632, while cash ended at $619,576.

• ·IPO underwriter's discounts and commissions payment: $250,000
• ·Public warrants derivative liability: $8,162,700 as of Dec 31, 2025
• ·Initial classification of warrant liability - public (non-cash): $1,524,900
• ·Notes payable - related party repaid: $231,901 (after $59,000 proceeds)

30-03-2026

Electra Battery Materials Corp's 20-F Annual Report for the year ended December 31, 2025, shows significant improvements in liquidity risk, with short-term liabilities (<1 year) decreasing 44% to $6,623 from $11,797 in 2024, primarily due to the absence of convertible notes payable. Medium-term (1-2 years) liabilities dropped over 99% to $79 from $9,755, and long-term (>2 years) liabilities declined 59% to $44,045 from $107,633. Foreign currency net USD exposure also improved markedly, reducing to -$16,128 CAD from -$65,132 CAD, driven by higher cash balances and lower debt.

• ·2025 short-term liabilities include accounts payable and accrued liabilities of $5,817 and deferred government grant of $642.
• ·Convertible notes payable of $8,057 (<1 year), $8,012 (1-2 years), and $99,071 (>2 years) present in 2024 liquidity table but absent in 2025.
• ·2025 USD-denominated cash and cash equivalents rose to $25,019 (CAD) from $3,391 (CAD) in 2024.

30-03-2026

AB Private Credit Investors Corp and multiple affiliated Borrowers and General Partners entered into the Eighteenth Amendment to their Revolving Credit Agreement originally dated June 14, 2019, with HSBC Bank USA, National Association as Administrative Agent, effective as of March 23, 2026. The amendment modifies certain sections and schedules of the Credit Agreement as set forth in Annex A (not provided), subject to conditions including execution, beneficial ownership certifications, and payment of fees. All parties reaffirmed the validity of liens, resolutions, and obligations under the Loan Documents, with representations that no Potential Default or Event of Default exists.

• ·Original Revolving Credit Agreement dated June 14, 2019.
• ·This is the eighteenth amendment; prior amendments listed from December 23, 2020 through December 8, 2025.
• ·Governing law: State of New York.
• ·SEC Filing Date: March 30, 2026; Items: 1.01, 2.03, 9.01.

30-03-2026

Vine Hill Capital Investment Corp. II (VHCP), a SPAC, filed its 10-K annual report on March 30, 2026, including audited financial statements for the period from inception on August 18, 2025, to December 31, 2025. The filing outlines strategies for transforming target businesses post-business combination to accelerate revenue growth and improve margins, while highlighting risks such as substantial debt service reducing cash available for dividends and operations, limitations on borrowing, and potential change of control from share issuances exceeding 60% of equity proceeds.

• ·Financial statements cover period from August 18, 2025 (inception) to December 31, 2025
• ·Includes Balance Sheet as of December 31, 2025; Statement of Operations; Statement of Changes in Shareholders’ Deficit; Statement of Cash Flows
• ·Risk of change of control if substantial ordinary shares issued

30-03-2026

CISO Global serves more than 437 clients across diverse sectors, with penetration of only approximately 20% for multiple services, positioning the company for revenue growth through cross-selling and upselling. However, it incurred significant operating losses during the years ended December 31, 2025 and 2024, has limited cash flow, and faces substantial doubt about its ability to continue as a going concern, with the auditor's opinion including an explanatory paragraph on this matter. The filing highlights strategic strengths like proprietary software and partnerships alongside extensive risk factors including talent shortages, long sales cycles, and competitive pressures.

• ·Dependence on a significant customer for a material portion of revenue and accounts receivable.
• ·Expectation not to pay cash dividends in the foreseeable future.
• ·Industry shortage of qualified compliance and cybersecurity professionals.
• ·Long and unpredictable sales cycles.
• ·Auditor’s opinion on financial statements for year ended December 31, 2025, includes going concern explanatory paragraph.

30-03-2026

Carlyle Private Equity Partners Fund, L.P. (CPEP) reported total net assets of $46,182 and total assets of $59,046 as of December 31, 2025, for the period from inception on February 11, 2025, driven by $46,997 in proceeds from unit issuances. Investments at fair value totaled $44,900 (cost basis $41,722), representing 97.22% of net assets, with cash and cash equivalents at $11,176; however, there was a net decrease in net assets resulting from operations of $(740). Net cash used in operating activities was $(35,820), offset by strong financing inflows.

• ·Cost of investments purchased: $42,076; Proceeds from sales and repayments: $408
• ·Net realized gain on investments: $(55); Net change in unrealized appreciation on investments: $(3,177)
• ·Equity securities purchases: $33,823; Net change in unrealized appreciation on equity securities still held: $2,139
• ·Level III valuation: Discount rate weighted average 12.19% (range 8.20%-16.78%), Terminal growth rate 4.28% (2.00%-11.00%)
• ·Total investments cost breakdown: $29,034 Americas, $9,095 Europe, $3,478 Australia, $7,850 Japan, $3,098 Other Asia

30-03-2026

Baker Hughes Co's DEF 14A Proxy Statement filed March 30, 2026, discloses 5% shareholders including The Vanguard Group (121,897,643 shares, 12.29%), JPMorgan Chase & Co. (86,781,218 shares, 8.75%), BlackRock Inc. (84,558,359 shares, 8.53%), and State Street Corporation (65,170,011 shares, 6.57%), with 991,757,347 Class A Common Stock shares outstanding as of March 23, 2026. Current directors, nominees, and executive officers as a group beneficially own 1,839,049 shares (less than 1%), including vested DSUs for directors ranging from 0 to 53,880.774 as of December 31, 2025. Related party transactions include $250,000 compensation in 2025 to an immediate family member of CEO Lorenzo Simonelli and $150,000 annual compensation approved for the son of director Cynthia B. Carroll effective April 2026.

• ·Company's Insider Trading Policy prohibits directors and executive officers from derivative transactions in Company stock and pledging shares as collateral.
• ·No personal loans or extensions of credit to directors or executive officers.
• ·Governance & Corporate Responsibility Committee reviews related person transactions per Item 404 of Regulation S-K.

30-03-2026

GBank Financial Holdings Inc. reported net income of $20.9 million for the year ended December 31, 2025, up 12% from $18.6 million in 2024, with diluted EPS increasing to $1.44 from $1.39 and loan growth of $143.3 million or 18% YoY. However, profitability metrics declined with return on average assets falling to 1.70% from 1.85%, return on average equity dropping to 13.61% from 16.14%, and net interest margin compressing to 4.33% from 4.79%, while non-performing assets rose sharply to $37.4 million or 2.75% of total assets from $14.2 million or 1.26%. Noninterest income surged 56.2% to $25.3 million driven by net interchange fees up 477% and loan servicing up 81%, but noninterest expenses increased 24.4% to $45.1 million.

• ·Average earning assets increased to $1,171.8 million in 2025 from $963.9 million in 2024.
• ·Total interest-bearing deposits grew to $806.1 million average in 2025 from $622.6 million in 2024.
• ·Guaranteed loans totaled $229.7 million as of Dec 31, 2025, slightly down from $233.9 million as of Dec 31, 2024.
• ·Net interest income rose $4.5 million or 9.8% to $50.7 million in 2025.

30-03-2026

Leidos Holdings, Inc. (NYSE: LDOS) completed its approximately $2.4 billion acquisition of ENTRUST Solutions Group from Kohlberg on March 30, 2026, effectively doubling its presence in the energy infrastructure market and adding more than 3,100 professionals with expertise in electric grid and natural gas infrastructure. The deal expands Leidos' engineering capabilities across power delivery and broadens its utility customer base, supporting the NorthStar 2030 strategy amid rising power demand. Leidos, with 47,000 global employees, reported approximately $17.2 billion in annual revenues for the fiscal year ended January 2, 2026.

• ·ENTRUST operates across 40+ locations in North America
• ·Leidos headquartered in Reston, Virginia

30-03-2026

Connect Biopharma announced positive topline results from its Phase 1 study (CBP-201-105) of intravenous rademikibart (300 mg, 2-minute IV push) in asthma and COPD patients, showing rapid FEV1 improvements of ≥200 mL in many patients as early as 15 minutes post-dosing, with mean improvements of ~200-400 mL maintained through Day 29 versus placebo decline. The treatment was generally well-tolerated with no serious adverse events, no severe AEs, and no discontinuations. Ongoing Phase 2 Seabreeze STAT studies expect topline data in mid-2026.

• ·Mean baseline FEV1: 1.9 L (asthma), 1.55 L (COPD)
• ·Randomized 4:1 rademikibart:placebo
• ·Exclusive license to Simcere for rademikibart in Greater China with royalties up to low double-digits
• ·Conference call and webcast on March 30, 2026 at 8:00 a.m. ET

30-03-2026

PMGC Holdings Inc. reported flat revenue of 590,084 and gross profit of 185,314 for the year ended December 31, 2025, unchanged from 2024. However, total operating expenses nearly doubled to 7,067,262 from 3,663,566, driven by increases in office and administration (105%), professional fees (153%), and consulting fees (29%), while marketing and promotion declined 31%; this resulted in a widened net loss of 7,780,740 from 4,016,714. The company stated no intention to declare dividends, with returns dependent on stock appreciation, and highlighted risks in its acquisition-driven growth strategy.

• ·No intention to declare dividends on Common Stock in the foreseeable future.
• ·Other income (expense) worsened to $(867,820) from $(353,148).
• ·Weighted average shares outstanding increased from 947 to 20,352.

30-03-2026

Capstone Green Energy Holdings, Inc. (CGEH) announced a $112.5 million strategic investment led by Monarch Alternative Capital LP, consisting of $80 million in new senior convertible preferred stock and $15 million in common stock from Monarch, plus a $17.5 million PIPE from existing investors. $85 million of proceeds will redeem legacy preferred equity held by a Goldman Sachs affiliate, simplifying the capital structure and making Capstone Green Energy LLC a wholly owned subsidiary. Remaining funds support general working capital and growth initiatives, including AI data center expansion, with board expansion to seven members including two Monarch appointees and a path to national exchange listing.

• ·Preferred Stock convertible at $5.00 per share, 5.00% PIK dividend, senior ranking, mandatory conversion if stock trades above $15.00 for 20 of 30 days.
• ·PIPE priced at $4.50 per share.
• ·45-day lock-up for Company directors and executives.
• ·Resale registration statement to be filed within 30 days of closing.
• ·Initial listing application for national exchange within 12 months.
• ·Expected closing on or about March 31, 2026.

30-03-2026

Douglas G. Thompson resigned as CEO and Managing Director effective March 31, 2026, to pursue new opportunities, leading the Board to reduce its size from seven to six members. Garold Spindler, age 78 and current Executive Chair with extensive coal industry experience, was appointed Interim CEO effective April 1, 2026, under a new employment agreement with an annual base salary of $1,250,000. Additionally, Greg Pritchard was appointed Board Chair effective the same date.

• ·Mr. Thompson informed of resignation on February 22, 2026 (February 23 in Australia).
• ·Mr. Spindler previously served as CEO from August 2018 to May 2023.
• ·Employment agreement dated March 27, 2026; terminable with 30 days' notice; includes 1-year non-compete.
• ·No family relationships or related party transactions with Mr. Spindler.

30-03-2026

Eikon Therapeutics reported a widened net loss of $324,248 thousand for the year ended December 31, 2025, up 33% from $243,814 thousand in 2024, driven by total operating expenses rising 30% to $338,945 thousand with R&D up 22% and G&A up 59%. While the company raised $352,053 thousand through financing activities including Series D preferred stock issuance netting $350,153 thousand, operating cash use increased 40% to $188,516 thousand and cash & equivalents fell to $104,901 thousand from $129,179 thousand. Total assets grew to $594,734 thousand supported by higher marketable securities of $231,074 thousand, though stockholders' deficit deepened to $879,034 thousand.

• ·Impairment of operating lease right-of-use assets: $10,275 thousand in 2025
• ·Impairment of property and equipment: $10,951 thousand in 2025
• ·Net loss per share basic and diluted: $(115.29) in 2025 vs $(96.76) in 2024
• ·Stock-based compensation expense: $18,036 thousand in 2025 (up from $12,429 thousand)
• ·Purchase of marketable securities: $444,102 thousand in 2025
• ·Proceeds from maturities of marketable securities: $309,500 thousand in 2025

30-03-2026

ECARX Holdings Inc. reported total revenues of $847,858 thousand for the year ended December 31, 2025, up 9.9% YoY from $771,530 thousand in 2024, primarily driven by 15.0% growth in sales of goods revenues to $703,093 thousand. However, software license revenues declined 30.0% to $29,698 thousand, service revenues fell 2.3% to $115,067 thousand, and gross profit was nearly flat at $161,262 thousand with gross margin contracting 1.8pp to 19.0%. Operating loss narrowed to $54,773 thousand from $122,896 thousand, and net loss improved to $68,939 thousand from $137,751 thousand.

• ·Research and development expenses declined to $123,337 thousand in 2025 from $174,864 thousand in 2024.
• ·Selling, general and administrative expenses decreased to $93,841 thousand in 2025 from $108,195 thousand in 2024.
• ·Total operating expenses fell to $216,035 thousand in 2025, or 25.5% of revenues, from $282,995 thousand in 2024.

30-03-2026

Aquestive Therapeutics, Inc. issued a press release on March 30, 2026, announcing the successful completion of an in-person Type A meeting with the FDA and receipt of preliminary comments regarding the resubmission of its New Drug Application (NDA) for Anaphylm™ (dibutepinephrine) sublingual film. The product is intended for the treatment of Type 1 allergic reactions, including anaphylaxis. No financial metrics or comparative data were disclosed.

30-03-2026

Benchmark 2025-V19 Mortgage Trust filed its Form 10-K annual report for the fiscal year ended December 31, 2025, on March 30, 2026, including assessments of compliance with servicing criteria and servicer compliance statements from entities like Midland Loan Services and Citibank, N.A. Explanatory notes highlight that key mortgage loans—Empire Mall (6.8% of initial pool), 9911 Belward (4.1%), 1700 Pavillion (3.4%), and Central Arts Plaza (1.2%)—are parts of loan combinations serviced under separate PSAs such as WFCM 2025-5C7 and Benchmark 2025-V18. No material legal proceedings, significant obligors, or external credit enhancements are reported, with most traditional financial sections omitted as is standard for such trusts.

• ·No mortgage loan in the pool constitutes a significant obligor per Item 1101(k)(2) of Regulation AB.
• ·No external credit enhancement, derivative instruments, or other support for certificates.
• ·No unresolved staff comments, legal proceedings material to security holders, or cybersecurity disclosures required.

30-03-2026

The 10-K annual report for STRATS(SM) Trust for Goldman Sachs Group Securities, Series 2006-2 (GJS), filed on March 30, 2026, includes a Regulation AB servicing criteria compliance table. It outlines general servicing considerations and cash collection/administration procedures, marking criteria as performed directly by the company (e.g., monitoring triggers, outsourcing oversight, payment deposits, wire disbursements, account maintenance), by vendors responsible to the company, or not applicable (e.g., back-up servicer, fidelity bond, advances, aggregation accuracy). No deficiencies or non-compliance issues are reported.

30-03-2026

Intellinetics reported Q4 2025 total revenue of $4.3 million, up 1.0% YoY to $4,323,843 driven by 8.4% SaaS growth to $1,603,641, though professional services declined 1.8% and net loss widened to $207,975 ($0.05/share) from $53,701 ($0.01/share). For full-year 2025, total revenue fell 8.0% YoY to $16,583,446 due to an 18.7% drop in professional services despite 11.3% SaaS growth to $6,331,167, with gross profit down 3.7%, net loss expanding to $1,872,895 ($0.44/share) from $546,215 ($0.13/share), and Adjusted EBITDA declining to $469,694 from $2,382,357. Management anticipates SaaS growth in 2026 amid focus on software-led expansion.

• ·Q4 Adjusted EBITDA $260,749 vs $531,241 YoY (decline).
• ·FY gross profit margin increased 295 basis points despite volume decline.
• ·Cash balance $2,528,281 at Dec 31, 2025 (up slightly from $2,489,236).
• ·Total current liabilities decreased to $5,056,120 from $6,597,773.

30-03-2026

CVD Equipment Corporation reported Q4 2025 revenue of $5.0 million, down 33.1% YoY, gross margin of 22.1% versus 26.4%, and a net loss of $1.3 million compared to net income of $0.1 million in the prior year quarter. For FY 2025, revenue fell 4.1% to $25.8 million with improved gross margin of 28.3% versus 22.5%, narrowing the net loss to $1.6 million from $1.9 million, though cash decreased to $8.7 million from $12.6 million. The company entered a definitive agreement to sell its SDC division to Atlas Copco Group for $16.9 million in cash (net ~$15.0 million), expected to close in Q2 2026.

• ·Implemented workforce reduction expected to save $1.8M in annual operating costs starting FY 2026.
• ·SDC sale includes retention of Saugerties facility with 2-year lease to buyer.
• ·Conference call scheduled for March 30, 2026 at 5:00 PM ET.

30-03-2026

ARKO Petroleum Corp. reported total revenues of $5,581,264 thousand for FY 2025, down 12.3% YoY from $6,367,739 thousand amid declines in fuel revenues (-4.4% for third-party, significant drop in related party) and total fuel gallons sold (-5.9% to 2,005,810 thousand gallons). Net income fell 18.6% to $32,727 thousand while operating income decreased 8.7% to $83,931 thousand; however, Adjusted EBITDA improved 3.1% to $143,513 thousand supported by higher fuel margins (10.3 cents per gallon total, up from 9.9) and growth in certain segment contributions like proprietary cardlock.

• ·Net cash used in investing activities FY2025: $(22,185) thousand, up from $(9,440) thousand in FY2024.
• ·Ratio of Net Debt to Adjusted EBITDA as of Dec 31 2025: 3.7x.
• ·Net cash provided by operating activities declined to $79,558 thousand in FY2025 from $106,757 thousand in FY2024.